IDMC-13 Families Day Webinar

Clinical trials have already begun

Myotonic Dystrophy: The Development of Therapeutic Drugs and the Future

Saturday, June 25, 2022, 9:00 am (JST)

Commemorative Event at the International Myotonic Dystrophy Consortium Meeting (IDMC-13)

Online webinar with consecutive interpretation in Japanese and English

This will be a Zoom webinar event. You can join online with Japanese and English interpretation services.

Lecture on therapeutic drugs that are already in or close to clinical trials

Cutting-edge pharmaceutical development will bring hope to patients and their families. Patients, families, friends, as well as doctors, researchers and pharmaceutical companies, etc. are all welcome to participate.

What is HAL, the robotic suit for medical use?
What is the combination remedy with therapeutic drugs?

There will be a presentation about HAL, a medical robotic suit, which is supposedly effective for myotonic dystrophy.

Let's join a Q&A session

We will use the Q&A feature of Zoom. Consecutive interpretation is provided, so you can ask questions even if you speak a different language.

*We may not be able to answer all questions due to time constraints.


Attendee-only video access

An on-demand video recording of the event will be available for two months after the conference.

We would appreciate your donations!

To support our future activities, donations will be greatly appreciated. Please feel free to donate any amount you feel comfortable with.


IDMC-13 Families Day Webinar "Clinical trials have already begun" Detailed Program

*The above times are Japan time (JST). Please confirm the time in your region.

AMO Pharma

Mike Snape, CSO

AMO-02 for congenital myotonic dystrophy: an update on progress

Avidity Biosciences

Lisa Ackermann, PhD, SVP Clinical Development.

Avidity: Ongoing Clinical Trial for DM1

Dyne Therapeutics

Molly White, Vice President, Global Head of Patient Advocacy and Engagement

Advancing The Treatment Paradigm for Myotonic Dystrophy Type 1

Department of Neurology, Osaka University Graduate School of Medicine

Masayuki Nakamori, MD., Ph. D.

An investigator-initiated clinical trial (MYD-0124) for treatment of myotonic dystrophy in Japan

National Hospital Organization Niigata National Hospital,
National Hospital Organization Sendai-Nishitaga Hospital

Takashi Nakajima, MD., Ph. D. and Toshiaki Takahashi, MD., Ph. D.

Innovative motor learning therapy with the wearable cyborg Hybrid Assistive Limb, HAL for neuromuscular diseases, including myotonic dystrophy

Houston Methodist Neuroscience Research Program

Tetsuo Ashizawa, M.D.

Clinical Trials in Myotonic Dystrophy and Beyond




  • You will need Zoom to participate.
  • Q&A sessions will be conducted via Zoom’s Q&A feature.
  • If you set your smartphone to block incoming calls, please make sure to receive mails from and before registering.

Contact Us

Myotonic Dystrophy Patients' Group of Japan (DM-family)
contact[at mark]

We only accept inquiries by email. Please note that we cannot respond to questions concerning Zoom operations.

The 13th International Myotonic Dystrophy Consortium Meeting

Myotonic Dystrophy Patients' Group of Japan (DM-family)